Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks
This ITC found no significant differences in time to beginning of symptom relief and overall treatment-related treatment-emergent adverse events between sebetralstat and rhC1INH.
Authors
- Paul K. Audhya
- Timothy Craig (ORCID: https://orcid.org/0000-0002-7774-4855)
- H. Henry Li
- Jonathan A. Bernstein (ORCID: https://orcid.org/0000-0002-3476-1196)
- Emel Aygören‐Pürsün
- Alice Wang (ORCID: https://orcid.org/0000-0002-0325-6832)
- Michael Manning (ORCID: https://orcid.org/0000-0003-4455-7356)
- James Morris
- Shuai Fu (ORCID: https://orcid.org/0000-0003-1810-2876)
- Agnieszka Kopiec
- Markus Magerl
- Noemi Hummel (ORCID: https://orcid.org/0009-0000-5656-5025)
Institutions
- Goethe University Frankfurt (DE)
- University of Arizona (US)
- Humboldt-Universität zu Berlin (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Vinmec Times City International Hospital (VN)
- Bernstein Clinical Research Center (US)
- Institute for Asthma and Allergy (US)
- KalVista Pharmaceuticals (United States) (US)
- University Hospital Frankfurt (DE)
- Cogent (United Kingdom) (GB)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Penn State Milton S. Hershey Medical Center (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Allergy Asthma and Clinical Immunology
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1186/s13223-025-00955-6
- Citations
- 2
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 3.25